Tissue Engineering and Regeneration - Technologies and Global Markets - Expected to Reach $60.8 Billion by 2021 - Research and Markets
X4 Pharmaceuticals Appoints Nancy Lurker as Chair of Board of Directors
Alnylam Reports Positive Initial Results from Ongoing Phase 1/2 Study of ALN-GO1, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1
A roundup of investment news.
Focusing on stocks with the most visible cash flows has been a winning strategy, and this screen can find them.
This screen finds stocks that would make it into Morningstar's Wide-Moat Focus strategy.
Who's in front heading 'round the bend?
Morningstar analysts see pharmaceuticals as 2010's hot zone for mergers and acquisitions.
Plus, Vanguard says 401(k) investors stayed the course in 2008, Macquarie Group buys Delaware Investments, more leveraged ETF warnings, and more.